|
End-of-day quote
Shenzhen S.E.
2026-09-18
|
5-day change | 1st Jan Change | ||
| 10.84 CNY | +1.03% |
|
-0.46% | -15.71% |
Company Valuation: Yixintang Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 22,959 | 18,782 | 13,803 | 7,625 | 7,383 | 6,224 | - | - |
| Change | - | -18.19% | -26.51% | -44.76% | -3.16% | -15.71% | - | - |
| Enterprise Value (EV) 1 | 21,903 | 16,608 | 11,574 | 5,707 | 6,451 | 4,985 | 4,800 | 4,432 |
| Change | - | -24.17% | -30.31% | -50.69% | 13.04% | -22.73% | -3.71% | -7.66% |
| P/E | 24.7x | 18.6x | 25.2x | 67.6x | 28.1x | 13.8x | 11.6x | 9.59x |
| PBR | 3.49x | 2.53x | 1.78x | 1.02x | 1.03x | 0.84x | 0.81x | 0.77x |
| PEG | - | 2.14x | -0.6x | -0.9x | 0x | 0.2x | 0.6x | 0.5x |
| Capitalization / Revenue | 1.57x | 1.08x | 0.79x | 0.42x | 0.43x | 0.35x | 0.33x | 0.31x |
| EV / Revenue | 1.5x | 0.95x | 0.67x | 0.32x | 0.37x | 0.28x | 0.26x | 0.22x |
| EV / EBITDA | 16.9x | 11x | 10.6x | 3.13x | 9x | 2.66x | 2.28x | 1.84x |
| EV / EBIT | 20.5x | 13.4x | 11.8x | 20.5x | 15.3x | 6.81x | 5.69x | 4.44x |
| EV / FCF | - | - | 6.14x | 3.89x | 4.76x | 4.53x | 3.18x | 2.36x |
| FCF Yield | - | - | 16.3% | 25.7% | 21% | 22.1% | 31.5% | 42.5% |
| Dividend per Share 2 | 0.3 | 0.4 | 0.4 | 0.3 | 0.2 | 0.3607 | 0.4926 | 0.6117 |
| Rate of return | 0.78% | 1.27% | 1.73% | 2.3% | 1.56% | 3.33% | 4.54% | 5.64% |
| EPS 2 | 1.561 | 1.697 | 0.9206 | 0.1927 | 0.4571 | 0.7851 | 0.9351 | 1.13 |
| Distribution rate | 19.2% | 23.6% | 43.4% | 156% | 43.8% | 45.9% | 52.7% | 54.1% |
| Net sales 1 | 14,585 | 17,432 | 17,380 | 18,000 | 17,336 | 17,571 | 18,586 | 19,934 |
| EBITDA 1 | 1,295 | 1,511 | 1,087 | 1,823 | 716.6 | 1,874 | 2,101 | 2,411 |
| EBIT 1 | 1,066 | 1,243 | 982.9 | 278 | 422.4 | 731.7 | 844 | 997.9 |
| Net income 1 | 921.5 | 1,010 | 549.4 | 114.1 | 263.4 | 456.2 | 546.7 | 663.5 |
| Net Debt 1 | -1,056 | -2,174 | -2,229 | -1,917 | -932 | -1,239 | -1,424 | -1,791 |
| Reference price 2 | 38.51 | 31.51 | 23.16 | 13.02 | 12.86 | 10.84 | 10.84 | 10.84 |
| Nbr of stocks (in thousands) | 596,181 | 596,071 | 596,005 | 585,604 | 574,128 | 574,128 | - | - |
| Announcement Date | 3/14/22 | 3/17/23 | 3/19/24 | 4/27/25 | 4/28/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 13.67x | 0.28x | 2.63x | 3.36% | 919M | ||
| 15.81x | 0.61x | 9.1x | -.--% | 14.11B | ||
| 16.54x | 0.74x | 7.74x | 2.25% | 6.45B | ||
| 19.56x | 0.72x | 12.19x | 1.28% | 6.07B | ||
| 14.65x | 0.9x | 6.28x | 2.89% | 4.11B | ||
| 14.19x | 1.22x | 7.46x | 5.7% | 3.14B | ||
| 14.05x | 0.59x | 4.57x | 5.14% | 3.11B | ||
| 36.7x | - | - | - | 2.85B | ||
| 14.32x | 0.86x | 6.44x | 4.54% | 2.97B | ||
| Average | 17.72x | 0.74x | 7.05x | 3.15% | 4.86B | |
| Weighted average by Cap. | 17.30x | 0.73x | 8.25x | 2.07% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 002727 Stock
- Valuation Yixintang Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
















